Last reviewed · How we verify

Abrocitinib Suspension F2 (abrocitinib-suspension-f2)

Pfizer · FDA-approved active Quality 35/100

Abrocitinib Suspension F2 (generic name: abrocitinib-suspension-f2) is a unknown drug developed by Pfizer. It is currently FDA-approved for Moderate to severe atopic dermatitis.

Abrocitinib Suspension F2, developed by Pfizer Inc., is a marketed drug for moderate to severe atopic dermatitis. It has generated $21.2B in revenue. The mechanism of action is not specified on Wikipedia. Abrocitinib Suspension F2 has 1 trial and 0 publications. It is a significant commercial product. There are no pipeline developments mentioned.

At a glance

Generic nameabrocitinib-suspension-f2
SponsorPfizer
Drug classunknown
Targetunknown
Therapeutic areaImmunology
PhaseFDA-approved
Annual revenue284

Approved indications

Common side effects

No common side effects on file.

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results
SEC EDGARRevenue + earnings

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Abrocitinib Suspension F2

What is Abrocitinib Suspension F2?

Abrocitinib Suspension F2 (abrocitinib-suspension-f2) is a unknown drug developed by Pfizer, indicated for Moderate to severe atopic dermatitis.

What is Abrocitinib Suspension F2 used for?

Abrocitinib Suspension F2 is indicated for Moderate to severe atopic dermatitis.

Who makes Abrocitinib Suspension F2?

Abrocitinib Suspension F2 is developed and marketed by Pfizer (see full Pfizer pipeline at /company/pfizer).

What is the generic name of Abrocitinib Suspension F2?

abrocitinib-suspension-f2 is the generic (nonproprietary) name of Abrocitinib Suspension F2.

What drug class is Abrocitinib Suspension F2 in?

Abrocitinib Suspension F2 belongs to the unknown class. See all unknown drugs at /class/unknown.

What development phase is Abrocitinib Suspension F2 in?

Abrocitinib Suspension F2 is FDA-approved (marketed).

What is Abrocitinib Suspension F2's annual revenue?

Abrocitinib Suspension F2 generated approximately $0.0B in annual revenue.

What does Abrocitinib Suspension F2 target?

Abrocitinib Suspension F2 targets unknown and is a unknown.

Related